Wedbush Sticks to Their Hold Rating for Lennar (LEN)
In a report released today, Nick Setyan from Wedbush maintained a Hold rating on Lennar (LEN – Research Report), with a price target of ...
Monte Rosa Therapeutics price target raised to $17 from $15 at Wedbush
Wedbush raised the firm’s price target on Monte Rosa Therapeutics (GLUE) to $17 from $15 and keeps an Outperform rating on the shares after the ...